Selected research
Industry Growth & Trends
Global Circulating Tumor Cell(CTC)Detection Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Circulating Tumor Cell(CTC)Detection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Circulating Tumor Cell(CTC)Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Circulating Tumor Cell(CTC)Detection market include Rarecyte, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE and Qiagen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Circulating Tumor Cell(CTC)Detection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Circulating Tumor Cell(CTC)Detection market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Circulating Tumor Cell(CTC)Detection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Circulating Tumor Cell(CTC)Detection.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Circulating Tumor Cell(CTC)Detection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Circulating Tumor Cell(CTC)Detection Market by Company
Rarecyte
ANGLE plc
Biocept Inc.
Bio-Rad Laboratories Inc.
Fluxion Biosciences Inc.
F. Hoffmann-La Roche AG
Sysmex Europe SE
Qiagen
Circulating Tumor Cell(CTC)Detection Segment by Type
Epithelial Cell Phenotype
Mesenchymal Cell Phenotype
Mixed Epithelial-Mesenchymal Phenotype
Circulating Tumor Cell(CTC)Detection Segment by Application
Cancer Diagnosis
Tumor Dynamic Assessment
Tumor Recurrence Monitoring
Circulating Tumor Cell(CTC)Detection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cell(CTC)Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cell(CTC)Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cell(CTC)Detection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Circulating Tumor Cell(CTC)Detection companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Epithelial Cell Phenotype
- Mesenchymal Cell Phenotype
- Mixed Epithelial-Mesenchymal Phenotype
Applications
- Cancer Diagnosis
- Tumor Dynamic Assessment
- Tumor Recurrence Monitoring
Companies covered
- Rarecyte
- ANGLE plc
- Biocept Inc.
- Bio-Rad Laboratories Inc.
- Fluxion Biosciences Inc.
- F. Hoffmann-La Roche AG
- Sysmex Europe SE
- Qiagen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Circulating Tumor Cell(CTC)Detection Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2021-2032)
- 1.4.1 Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2021-2026)
- 1.4.2 Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2027-2032)
- 1.5 Key Regions Circulating Tumor Cell(CTC)Detection Market Size (2021-2032)
- 1.5.1 North America Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (2021-2032)
- 1.5.4 South America Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (2021-2032)
2 Circulating Tumor Cell(CTC)Detection Market by Type
- 2.1 Type Introduction
- 2.1.1 Epithelial Cell Phenotype
- 2.1.2 Mesenchymal Cell Phenotype
- 2.1.3 Mixed Epithelial-Mesenchymal Phenotype
- 2.2 Global Circulating Tumor Cell(CTC)Detection Market Size by Type
- 2.2.1 Global Circulating Tumor Cell(CTC)Detection Market Size Overview by Type (2021-2032)
- 2.2.2 Global Circulating Tumor Cell(CTC)Detection Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Circulating Tumor Cell(CTC)Detection Market Size Forecasted by Type (2027-2032)
- 2.3 Global Circulating Tumor Cell(CTC)Detection Market Size by Regions
- 2.3.1 North America Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Type (2021-2026)
3 Circulating Tumor Cell(CTC)Detection Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer Diagnosis
- 3.1.2 Tumor Dynamic Assessment
- 3.1.3 Tumor Recurrence Monitoring
- 3.2 Global Circulating Tumor Cell(CTC)Detection Market Size by Application
- 3.2.1 Global Circulating Tumor Cell(CTC)Detection Market Size Overview by Application (2021-2032)
- 3.2.2 Global Circulating Tumor Cell(CTC)Detection Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Circulating Tumor Cell(CTC)Detection Market Size Forecasted by Application (2027-2032)
- 3.3 Global Circulating Tumor Cell(CTC)Detection Market Size by Regions
- 3.3.1 North America Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Circulating Tumor Cell(CTC)Detection Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Circulating Tumor Cell(CTC)Detection Industry Trends
- 4.2 Circulating Tumor Cell(CTC)Detection Industry Drivers
- 4.3 Circulating Tumor Cell(CTC)Detection Industry Opportunities and Challenges
- 4.4 Circulating Tumor Cell(CTC)Detection Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Circulating Tumor Cell(CTC)Detection Revenue (2021-2026)
- 5.2 Global Circulating Tumor Cell(CTC)Detection Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Circulating Tumor Cell(CTC)Detection Key Company Headquarters & Area Served
- 5.4 Global Circulating Tumor Cell(CTC)Detection Company, Product Type & Application
- 5.5 Global Circulating Tumor Cell(CTC)Detection Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Circulating Tumor Cell(CTC)Detection Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Circulating Tumor Cell(CTC)Detection Players Market Share by Revenue in 2025
- 5.6.3 2025 Circulating Tumor Cell(CTC)Detection Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Rarecyte
- 6.1.1 Rarecyte Company Information
- 6.1.2 Rarecyte Business Overview
- 6.1.3 Rarecyte Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.1.5 Rarecyte Recent Developments
- 6.2 ANGLE plc
- 6.2.1 ANGLE plc Company Information
- 6.2.2 ANGLE plc Business Overview
- 6.2.3 ANGLE plc Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.2.5 ANGLE plc Recent Developments
- 6.3 Biocept Inc.
- 6.3.1 Biocept Inc. Company Information
- 6.3.2 Biocept Inc. Business Overview
- 6.3.3 Biocept Inc. Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.3.5 Biocept Inc. Recent Developments
- 6.4 Bio-Rad Laboratories Inc.
- 6.4.1 Bio-Rad Laboratories Inc. Company Information
- 6.4.2 Bio-Rad Laboratories Inc. Business Overview
- 6.4.3 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.4.5 Bio-Rad Laboratories Inc. Recent Developments
- 6.5 Fluxion Biosciences Inc.
- 6.5.1 Fluxion Biosciences Inc. Company Information
- 6.5.2 Fluxion Biosciences Inc. Business Overview
- 6.5.3 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.5.5 Fluxion Biosciences Inc. Recent Developments
- 6.6 F. Hoffmann-La Roche AG
- 6.6.1 F. Hoffmann-La Roche AG Company Information
- 6.6.2 F. Hoffmann-La Roche AG Business Overview
- 6.6.3 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.6.5 F. Hoffmann-La Roche AG Recent Developments
- 6.7 Sysmex Europe SE
- 6.7.1 Sysmex Europe SE Company Information
- 6.7.2 Sysmex Europe SE Business Overview
- 6.7.3 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.7.5 Sysmex Europe SE Recent Developments
- 6.8 Qiagen
- 6.8.1 Qiagen Company Information
- 6.8.2 Qiagen Business Overview
- 6.8.3 Qiagen Circulating Tumor Cell(CTC)Detection Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio
- 6.8.5 Qiagen Recent Developments
7 North America
- 7.1 North America Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 7.3 North America Circulating Tumor Cell(CTC)Detection Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 8.3 Europe Circulating Tumor Cell(CTC)Detection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Circulating Tumor Cell(CTC)Detection Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 10.3 South America Circulating Tumor Cell(CTC)Detection Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Circulating Tumor Cell(CTC)Detection Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst